Results 161 to 170 of about 3,778,390 (297)

Evolving antimicrobial resistance patterns in group B streptococci: A five-year study in a high-risk pregnancy referral center in northeastern Brazil. [PDF]

open access: yesRev Soc Bras Med Trop
Gomes JIAB   +7 more
europepmc   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

open access: yesMolecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge   +17 more
wiley   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Evaluation of recombinase polymerase amplification assays for targeted detection of bovine respiratory disease bacterial pathogens and antimicrobial-resistance genes in feedlot calves. [PDF]

open access: yesJ Vet Diagn Invest
Funk T   +12 more
europepmc   +1 more source

Resist resistance

open access: yes
This thesis explores changes in swallowing and communication following total laryngectomy (removal of the voice box). Chapter 1 outlines the anatomy and physiology of the pharynx and larynx, along with the functional changes that occur after the surgery.
openaire   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

open access: yesMolecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek   +2 more
wiley   +1 more source

Resisting resistance to cancer immunotherapy [PDF]

open access: yesThoracic Cancer, 2018
Lam, Walter Sze‐Tung   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy